Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CARGO Therapeutics, Inc. Common Stock

Healthcare US CRGX

NoneUSD
0.00(0%)

Last update at 2025-09-25T20:04:31.370751Z

Day Range

--
LowHigh

52 Week Range

13.1433.92
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap941.12M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-71.62900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Income before tax -40.95100M -5.85000M
Minority interest - -
Net income -40.95100M -5.85000M
Selling general administrative 5.40M 1.52M
Selling and marketing expenses - -
Gross profit - -
Reconciled depreciation 1.44M 0.15M
Ebit -34.79300M -5.85000M
Ebitda -33.34900M -5.70300M
Depreciation and amortization 1.44M 0.15M
Non operating income net other - -
Operating income -34.77100M -5.97700M
Other operating expenses 34.77M 5.98M
Interest expense 4.94M 0.00000M
Tax provision - -
Interest income - -
Net interest income -4.94200M 0.00000M
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense 4.92M 0.13M
Total revenue 0.00000M 0.00000M
Total operating expenses 34.77M 5.98M
Cost of revenue - -
Total other income expense net -1.23800M 0.13M
Discontinued operations - -
Net income from continuing ops -40.95100M -5.85000M
Net income applicable to common shares - -
Preferred stock and other adjustments - -
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 453.04M 10.24M 4.50M
Intangible assets - - -
Earning assets - - -
Other current assets - - -
Total liab 47.65M 45.48M 4.68M
Total stockholder equity 405.39M -35.23600M -0.17500M
Deferred long term liab - - -
Other current liab 1.03M 17.74M 0.69M
Common stock 0.04M 0.01M 0.01M
Capital stock 0.04M 0.03M 0.02M
Retained earnings -145.14600M -46.99900M -6.04800M
Other liab - - -
Good will - - -
Other assets - - -
Cash 405.73M 1.87M 0.04M
Cash and equivalents - - -
Total current liabilities 21.16M 44.14M 2.45M
Current deferred revenue 12.84M 4.65M 0.59M
Net debt -377.19100M 22.13M 3.13M
Short term debt 2.28M 22.91M 0.94M
Short long term debt - 21.91M -
Short long term debt total 28.54M 24.00M 3.17M
Other stockholder equity 550.49M 11.74M 5.86M
Property plant equipment - - -
Total current assets 409.48M 3.93M 0.18M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables 1.74M 0.48M -
Long term debt - - -
Inventory - - -
Accounts payable 5.01M 3.48M 0.82M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 4.96M 0.78M 0.44M
Deferred long term asset charges - - -
Non current assets total 43.56M 6.32M 4.32M
Capital lease obligations 28.54M 2.10M 3.17M
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Investments -3.28200M -0.44200M
Change to liabilities - -
Total cashflows from investing activities - -
Net borrowings - -
Total cash from financing activities 34.19M 5.41M
Change to operating activities - -
Net income -40.95100M -5.85000M
Change in cash 1.83M 0.03M
Begin period cash flow 0.04M 0.01M
End period cash flow 1.87M 0.04M
Total cash from operating activities -29.07200M -4.94200M
Issuance of capital stock 5.50M 5.41M
Depreciation 1.44M 0.15M
Other cashflows from investing activities - -
Dividends paid - -
Change to inventory - -
Change to account receivables - -
Sale purchase of stock - -
Other cashflows from financing activities -3.28200M -0.44200M
Change to netincome - -
Capital expenditures 3.28M 0.44M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital 2.97M 0.25M
Stock based compensation 0.30M 0.51M
Other non cash items 7.17M -
Free cash flow -32.35400M -5.38400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CRGX
CARGO Therapeutics, Inc. Common Stock		 - -% - - - - - -12.1597
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock

1900 Alameda De Las Pulgas, San Mateo, CA, United States, 94403

Key Executives

Name Title Year Born
Dr. Louai Labanieh Founder NA
Ms. Gina Chapman President, CEO & Director 1968
Dr. Crystal L. Mackall M.D. Co-Founder 1961
Dr. Shishir Gadam Ph.D. Chief Technical Officer 1967
Dr. Robbie Majzner M.D. Founder & Chair of Scientific Advisory Board NA
Ms. Nancy Goodman J.D. Founder NA
Mr. Anup Radhakrishnan CFO, Secretary & Chief Business Officer 1980
Dr. Corinne D. Epperly M.D., M.P.H. Chief Operating Officer 1978
Mr. Faisal Shawwa M.B.A. Senior Vice President of Finance & Accounting NA
Dr. Michael Ports Ph.D. Chief Scientific Officer 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions